US 11,851,499 B2
Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
Jay M. Short, Jackson, WY (US); Gerhard Frey, San Diego, CA (US); and Hwai Wen Chang, San Marcos, CA (US)
Assigned to BioAtla, Inc., San Diego, CA (US)
Appl. No. 17/616,113
Filed by BioAtla, Inc., San Diego, CA (US)
PCT Filed Jun. 10, 2020, PCT No. PCT/US2020/037096
§ 371(c)(1), (2) Date Dec. 2, 2021,
PCT Pub. No. WO2020/252095, PCT Pub. Date Dec. 17, 2020.
Claims priority of provisional application 62/860,092, filed on Jun. 11, 2019.
Prior Publication US 2022/0315664 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 47/6851 (2017.08); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 27 Claims
 
1. Isolated polypeptides comprising a heavy chain variable region and a light chain variable region that specifically bind to human EpCAM, wherein the heavy chain variable region includes three complementarity determining regions having sequences H1, H2, and H3, wherein:
the H1 sequence is GYTFTSYWMH (SEQ ID NO: 1);
the H2 sequence is X1IRPSTGYTEYNQKFKD (SEQ ID NO: 2); and
the H3 sequence is GDNWVGFAN (SEQ ID NO: 3); wherein X1 is Y or D; and
the light chain variable region includes three complementarity determining regions having sequences L1, L2, and L3, wherein:
the L1 sequence is SASSSISYMH (SEQ ID NO: 4);
the L2 sequence is STSNLX2S (SEQ ID NO: 5); and
the L3 sequence is X3QWSTYX4T (SEQ ID NO: 6); wherein X2 is A or H; X3 is H or E;
and X4 is H or E; and with the proviso that X1, X2, X3 and X4 cannot be Y, A, H, and H at the same time.